
Claims:


1. A pharmaceutical composition comprising a crystalline compound of Formula (I),



(I)

optionally together with a pharmaceutically acceptable carrier, diluent, or excipient; wherein the crystalline compound is in particulate form having an average particle size of less than about 5 μm.

2. A pharmaceutical composition comprising a crystalline form of a compound of Formula (I),



(I)

wherein the crystalline form is characterized by a powder x-ray diffraction pattern comprising the 2θ values 14.9 ± 0.1°, 16.7 ± 0.1° and 21.6 ± 0.1°, optionally together with a pharmaceutically acceptable carrier, diluent, or excipient.

3. The pharmaceutical composition of claim 2, wherein:
(i) the crystalline form is characterized by a powder x-ray diffraction pattern comprising the 2θ values 14.9 ± 0.1°, 16.7 ± 0.1°, 18.0 ± 0.1°, 21.6 ± 0.1° and 28.9 ± 0.1°; and/or
(ii) wherein the compound of Formula (I) has an average particle size of less than about 5 μm.

4. The pharmaceutical composition of claim 1, wherein the crystalline form is characterized by a powder x-ray diffraction pattern comprising the 2θ values 14.9 ± 0.1°, 16.7 ± 0.1° and 21.6 ± 0.1°, optionally wherein the crystalline form is characterized by a powder x-

ray diffraction pattern comprising the 2θ values 14.9 ± 0.1°, 16.7 ± 0.1°, 18.0 ± 0.1°, 21.6 ± 0.1° and 28.9 ± 0.1°.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the crystalline compound has an average particle size of less than about 2 μm, or less than about 1 μm.

6. The pharmaceutical composition of any one of claims 1 to 5, wherein:
(i) the crystalline compound has an average particle size and/or D50 value of from about 400 nm to about 900 nm, or from about 450 nm to about 750 nm;
(ii) the crystalline compound has a D10 value of from about 200 nm to about 600 μm, or from about 300 nm to about 500 nm; and/or
(iii) the crystalline compound has a D90 value of from about 500 nm to about 2,000 nm, or from about 700 nm to about 1,000 nm.

7. The pharmaceutical composition of any one of claims 1 to 6, wherein
(i) the crystalline compound has an onset melting temperature ($T_{m(onset)}$), from 121 °C to 122 °C when heated to 134 °C at a rate of 5 °C/min during Differential Scanning Calorimetry; and/or
(ii) the crystalline compound has a doublet peak in the range 1,650 to 1,700 cm^{-1} in an infrared spectrum, such as wherein the doublet peak is in the range 1,670 and 1,690 cm^{-1}.

8. The pharmaceutical composition of any one of claims 1 to 7, wherein the pharmaceutical composition comprises a thermoresponsive hydrogel, wherein the crystalline compound of formula (I) is dispersed in the hydrogel, and the pharmaceutical composition further comprises:
one or more poloxamers, wherein the total amount of poloxamers is from about 15% to about 20% by weight of the pharmaceutical composition;
from about 0.5% to about 2% by weight of polyvinylpyrrolidone;
from about 18% to about 20% by weight of polyethylene glycol;
and from about 0.2 to 0.3% by weight of a polysorbate.

9. The pharmaceutical composition of claim 8, wherein:
(i) the crystalline compound is present from about 1% to about 5% by weight of the pharmaceutical composition, such as about 2% by weight of the pharmaceutical composition;
(ii) the one or more poloxamers is selected from poloxamer 407 and poloxamer 188, optionally wherein the pharmaceutical composition comprises about 15% by weight of poloxamer 407 and from about 2.5% to about 5% by weight of poloxamer 188;
(iii) the pharmaceutical composition comprises about 1% of polyvinylpyrrolidone.
(iv) the polyethylene glycol has a molecular weight of about 350 to about 450 g/mol, optionally wherein the polyethylene glycol is polyethylene glycol 400;
(v) the pharmaceutical composition comprises from about 19% to about 20% by weight of the polyethylene glycol;

(vi) the polysorbate is polysorbate 80; and/or
(vii) the pharmaceutical composition comprises about 0.25% of the polysorbate.

10. The pharmaceutical composition of any one of claims 1 to 7, wherein the crystalline compound is dispersed in a carrier comprising one or more of a surfactant and a polymer, and optionally:
(a) wherein the crystalline compound is present from about 10% to about 40% by weight of the composition, and optionally from about 15% to about 30% by weight of the composition, or from about 20% to about 30% by weight of the composition;
(b) wherein the crystalline compound is present at a concentration of at least 1 mg/mL, optionally at a concentration of at least 2 mg/mL, and optionally at a concentration of at least 3 mg/mL; and/or
(c) wherein the composition comprises polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG), and optionally wherein the PCL-PVAc-PEG is present from about 10% to about 40% by weight of the composition, or from about 25% to about 35% by weight of the composition.

11. The pharmaceutical composition of claim 10, wherein the composition is a suspension comprising one or more poloxamers, optionally wherein the poloxamer(s) are selected from poloxamer 407, poloxamer 338, and poloxamer 188.

12. The pharmaceutical composition of claim 11, wherein the poloxamer(s) are present from about 10% to about 40% by weight of the composition, or from about 10% to about 30% by weight of the composition, or from about 15% to about 25% by weight of the composition, and wherein the poloxamer is optionally poloxamer 407.

13. The pharmaceutical composition of any one of claims 1 to 12, wherein the crystalline compound is non-encapsulated.

14. A pharmaceutical composition of any one of claims 1 to 13 for use in a method of treatment.

15. Use of a pharmaceutical composition of any one of claims 1 to 13 in the manufacture of a medicament for use in a method of treating cancer, optionally wherein the cancer is brain cancer, sarcoma, glioblastoma or soft-tissue sarcoma.